参考文献
[1] Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description[J]. Circulation, 2002,106(24):3006‑3008. DOI: 10.1161/01.cir.0000047200.36165.b8.
[2] Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right‑ventricle to pulmonary‑artery prosthetic conduit with valve dysfunction[J]. Lancet, 2000,356(9239):1403‑1405. DOI: 10.1016/S0140‑ 6736(00)02844‑0.
[3] Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur Heart J,2017,38(36):2739‑2791. DOI: 10.1093/eurheartj/ehx391.
[4] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2017,70(2):252‑289. DOI: 10.1016/j.jacc.2017.03.011.
[5] Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic‑valve replacement with a balloon‑expandable valve in low‑risk patients[J]. N Engl J Med, 2019,380(18):1695‑1705. DOI: 10.1056/NEJMoa1814052.
[6] Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic‑valve replacement with a self‑expanding valve in low‑risk patients[J]. N Engl J Med, 2019,380(18):1706‑1715. DOI: 10.1056/NEJMoa1816885.
[7] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2021,143(5):e72‑e227. DOI: 10.1161/CIR.0000000000000923.
[8] Sundt TM, Jneid H. Guideline Update on Indications for Transcatheter aortic valve implantation based on the 2020 American College of Cardiology/American Heart Association Guidelines for management of valvular heart disease[J]. JAMA Cardiol, 2021,6(9):1088‑1089. DOI: 10.1001/jamacardio.2021.2534.
[9] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561‑632. DOI: 10.1093/eurheartj/ehab395.
[10] 潘文志,周达新,葛均波. 全患群经导管主动脉瓣置换术:未来的终极目标[J/OL].中华心血管病杂志(网 络 版), 2018, 1: e1000005.(2018‑12‑12)[2022‑01‑05]. http://www.cvjc.org.cn/index.php/Column/columncon/article_id/166. DOI:10.3760/cma.j.issn.2096‑1588.2018.1000005.
[11] Deharo P, Bisson A, Herbert J, et al. Transcatheter valve‑in‑valve aortic valve replacement as an alternative to surgical re‑replacement[J]. J Am Coll Cardiol, 2020,76(5):489‑499. DOI: 10.1016/j.jacc.2020.06.010.
[12] Tam DY, Dharma C, Rocha RV, et al. Transcatheter ViV versus redo surgical AVR for the management of failed biological prosthesis: early and late outcomes in a propensity‑matched cohort[J]. JACC Cardiovasc Interv, 2020,13(6):765‑774. DOI: 10.1016/j.jcin.2019.10.030.
[13] Bleiziffer S, Simonato M, Webb JG, et al. Long‑term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves[J]. Eur Heart J, 2020,41(29):2731‑2742. DOI: 10.1093/eurheartj/ehaa544.
[14] Hirji SA, Percy ED, Zogg CK, et al. Comparison of in‑hospital outcomes and readmissions for valve‑in‑valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real‑world outcomes[J]. Eur Heart J, 2020,41(29):2747‑2755. DOI: 10.1093/eurheartj/ehaa252.
[15] Landes U, Sathananthan J, Witberg G, et al. Transcatheter replacement of transcatheter versus surgically implanted aortic valve bioprostheses[J]. J Am Coll Cardiol, 2021,77(1):1‑14. DOI: 10.1016/j.jacc.2020.10.053.
[16] Rodriguez‑Gabella T, Voisine P, Dagenais F, et al. Long‑term outcomes following surgical aortic bioprosthesis implantation[J]. J Am Coll Cardiol, 2018,71(13):1401‑1412. DOI: 10.1016/j.jacc.2018.01.059.
[17] Gleason TG, Reardon MJ, Popma JJ, et al. 5‑year outcomes of self‑expanding transcatheter versus surgical aortic valve replacement in high‑risk patients[J]. J Am Coll Cardiol, 2018,72(22):2687‑2696. DOI: 10.1016/j.jacc.2018.08.2146.
[18] Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk[J]. J Am Coll Cardiol, 2019,73(5):546‑553. DOI: 10.1016/j.jacc.2018.10.083.
[19] 宋光远, 王墨扬, 王媛, 等. Venus‑A主动脉瓣膜介入治疗重度主动脉瓣狭窄的效果[J].中华心血管病杂志,2017,45(10):843‑847. DOI: 10.3760/cma.j.issn.0253‑3758.2017.10.006.
[20] Liao YB, Li YJ, Xiong TY, et al. Comparison of procedural, clinical and valve performance results of transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic stenosis[J]. Int J Cardiol, 2018,254:69‑74. DOI: 10.1016/j.ijcard.2017.12.013.
[21] Zhou D, Pan W, Wang J, et al. VitaFlow™ transcatheter valve system in the treatment of severe aortic stenosis: one‑year results of a multicenter study[J]. Catheter Cardiovasc Interv, 2020,95(2):332‑338. DOI: 10.1002/ccd.28226.
[22] Liu XB, Jiang JB, Zhou QJ, et al. Evaluation of the safety and efficacy of transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic valve in a Chinese population[J]. J Zhejiang Univ Sci B, 2015,16(3):208‑214. DOI: 10.1631/jzus.B1500017.
[23] Halim SA, Edwards FH, Dai D, et al. Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry[J]. Circulation, 2020,141(13):1071‑1079. DOI: 10.1161/CIRCULATIONAHA. 119.040333.
[24] Forrest JK, Kaple RK, Ramlawi B, et al. Transcatheter aortic valve replacement in bicuspid versus tricuspid aortic valves from the STS/ACC TVT registry[J]. JACC Cardiovasc Interv, 2020,13(15):1749‑1759. DOI: 10.1016/j.jcin.2020.03.022.
[25] Zhang Y, Pan WZ, Guan LH, et al. Small balloon strategy associated with low pacemaker implantation rate after self‑expanding transcatheter valve implantation[J]. World J Emerg Med, 2021,12(1):48‑53. DOI: 10.5847/wjem.j.1920‑8642.2021.01.008.
[26] Liu X, He Y, Zhu Q, et al. Supra‑annular structure assessment for self‑expanding transcatheter heart valve size selection in patients with bicuspid aortic valve[J]. Catheter Cardiovasc Interv, 2018,91(5):986‑994. DOI: 10.1002/ccd.27467.
[27] 中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020 更新版)[J]. 中国介入心脏病学杂志, 2020,28(6):301‑309.DOI:10.3969/j.issn.1004‑8812.2020.06.001.
[28] Yoon SH, Kim WK, Dhoble A, et al. Bicuspid aortic valve morphology and outcomes after transcatheter aortic valve replacement[J]. J Am Coll Cardiol, 2020,76(9):1018‑1030. DOI: 10.1016/j.jacc.2020.07.005.
[29] Hardikar AA, Marwick TH. Surgical thresholds for bicuspid aortic valve associated aortopathy[J]. JACC Cardiovasc Imaging, 2013,6(12):1311‑1320. DOI: 10.1016/j.jcmg.2013.10.005.
[30] Lv WY, Zhao ZG, Li SJ, et al. Progression of the ascending aortic diameter after transcatheter aortic valve implantation: based on computed tomography images[J]. J Invasive Cardiol, 2019,31(8):E234‑E241.
[31] Itagaki S, Chikwe JP, Chiang YP, et al. Long‑term risk for aortic complications after aortic valve replacement in patients with bicuspid aortic valve versus marfan syndrome[J]. J Am Coll Cardiol, 2015,65(22):2363‑2369. DOI: 10.1016/j.jacc.2015.03.575.
[32] Khan JM, Dvir D, Greenbaum AB, et al. Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement: concept to first‑in‑human[J]. JACC Cardiovasc Interv, 2018,11(7):677‑689. DOI: 10.1016/j.jcin.2018.01.247.
[33] Khan JM, Greenbaum AB, Babaliaros VC, et al. BASILICA trial: one‑year outcomes of transcatheter electrosurgical leaflet laceration to prevent tavr coronary obstruction[J]. Circ Cardiovasc Interv, 2021,14(5):e010238. DOI: 10.1161/CIRCINTERVENTIONS.120.010238.
[34] Mercanti F, Rosseel L, Neylon A, et al. Chimney stenting for coronary occlusion during TAVR: insights from the chimney registry[J]. JACC Cardiovasc Interv, 2020,13(6):751‑761. DOI: 10.1016/j.jcin.2020.01.227.
[35] Palmerini T, Chakravarty T, Saia F, et al. Coronary protection to prevent coronary obstruction during TAVR: a multicenter international registry[J]. JACC Cardiovasc Interv, 2020,13(6):739‑747. DOI: 10.1016/j.jcin.2019.11.024.
[36] Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and management of valvular heart disease: the EURObservational research programme valvular heart disease II survey[J]. Circulation, 2019,140(14):1156‑1169. DOI: 10.1161/CIRCULATIONAHA.119.041080.
[37] Pan W, Zhou D, Cheng L, et al. Aortic regurgitation is more prevalent than aortic stenosis in Chinese elderly population: implications for transcatheter aortic valve replacement[J]. Int J Cardiol, 2015,201:547‑548. DOI: 10.1016/j.ijcard.2014.10.069.
[38] Huded CP, Allen KB, Chhatriwalla AK. Counterpoint: challenges and limitations of transcatheter aortic valve implantation for aortic regurgitation[J]. Heart, 2021,107(24):1942‑1945. DOI: 10.1136/heartjnl‑2020‑318682.
[39] Sawaya FJ, Deutsch MA, Seiffert M, et al. Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an international registry study[J]. JACC Cardiovasc Interv, 2017,10(10):1048‑1056. DOI: 10.1016/j.jcin.2017.03.004.
[40] Yoon SH, Schmidt T, Bleiziffer S, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation[J]. J Am Coll Cardiol, 2017,70(22):2752‑2763. DOI: 10.1016/j.jacc.2017.10.006.
[41] Wernly B, Eder S, Navarese EP, et al. Transcatheter aortic valve replacement for pure aortic valve regurgitation: "on‑label" versus "off‑label" use of TAVR devices[J]. Clin Res Cardiol, 2019,108(8):921‑930. DOI: 10.1007/s00392‑019‑01422‑0.
[42] Shi J, Wei L, Chen Y, et al. Transcatheter aortic valve implantation with J‑valve: 2‑year outcomes from a multicenter study[J]. Ann Thorac Surg, 2021,111(5):1530‑1536. DOI: 10.1016/j.athoracsur.2020.06.139.
[43] Mack MJ, Lindenfeld J, Abraham WT, et al. 3‑year outcomes of transcatheter mitral valve repair in patients with heart failure[J]. J Am Coll Cardiol, 2021,77(8):1029‑1040. DOI: 10.1016/j.jacc.2020.12.047.
[44] Bonow RO, O′Gara PT, Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2020,75(17):2236‑2270. DOI: 10.1016/j.jacc.2020.02.005.
[45] Mauri V, Besler C, Riebisch M, et al. German multicenter experience with a new leaflet‑based transcatheter mitral valve repair system for mitral regurgitation[J]. JACC Cardiovasc Interv, 2020,13(23):2769‑2778. DOI: 10.1016/j.jcin.2020.08.025.
[46] Zahr F, Song HK, Chadderdon SM, et al. 30‑day outcomes following transfemoral transseptal transcatheter mitral valve replacement: intrepid TMVR early feasibility study results[J]. JACC Cardiovasc Interv,2022,15(1):80‑89. DOI: 10.1016/j.jcin.2021.10.018.
[47] 宁小平, 安朝, 乔帆, 等. 经导管介入三尖瓣置换装置LuX-Valve在重度三尖瓣反流治疗中的应用[J] . 中华心血管病杂志, 2021, 49(5) : 455-460. DOI:10.3760/cma.j.cn112148-20210125-00091.
[48] Sun Z, Li H, Zhang Z, et al. Twelve‑month outcomes of the LuX‑Valve for transcatheter treatment of severe tricuspid regurgitation[J]. EuroIntervention, 2021,17(10):818‑826. DOI: 10.4244/EIJ‑D‑21‑00095.
[49] Baumgartner H, De Backer J, Babu‑Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease[J]. Eur Heart J, 2021,42(6):563‑645. DOI: 10.1093/eurheartj/ehaa554.
[50] 周达新, 潘文志, 管丽华, 等. 经皮肺动脉瓣置入二例报道[J].中国介入心脏病学杂志,2013,21(5):332‑334. DOI: 10.3969/j.issn.1004‑8812.2013.05.015.
[51] Zhou D, Pan W, Jilaihawi H, et al. A self‑expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one‑year results[J]. EuroIntervention, 2019,14(13):1371‑1377. DOI: 10.4244/EIJ‑D‑18‑00715.
[52] Morgan G, Prachasilchai P, Promphan W, et al. Medium‑term results of percutaneous pulmonary valve implantation using the Venus P‑valve: international experience[J]. EuroIntervention, 2019,14(13):1363‑1370. DOI: 10.4244/EIJ‑D‑18‑00299.
[53] Haas NA, Vcasna R, Laser KT, et al. The standing of percutaneous pulmonary valve implantation compared to surgery in a non‑preselected cohort with dysfunctional right ventricular outflow tract ‑reasons for failure and contraindications[J]. J Cardiol, 2019,74(3):217‑222. DOI: 10.1016/j.jjcc.2019.03.021.
[54] Esmaeili A, Bollmann S, Khalil M, et al. Percutaneous pulmonary valve implantation for reconstruction of a patch‑repaired right ventricular outflow tract[J]. J Interv Cardiol, 2018,31(1):106‑111. DOI: 10.1111/joic.12443.
[55] Maschietto N, Sperotto F, Esch JE, et al. The snared wire technique for Sapien valve implantation in the pulmonary position[J]. Catheter Cardiovasc Interv, 2020,96(4):898‑903. DOI: 10.1002/ccd.28970.